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Abstract:
Purpose of the article: This article presents results of an analysis of sustainable value added created by top 
5 European pharmaceutical companies in six different environmental resources. We compare value created 
in the respective companies to the target EU values. Our results show that in the year 2010 companies’ 
performance overcame set target.
Methodology/methods: Sustainable Value Added is a relatively new method. It was first introduced as a whole 
concept in 2004 and assesses how companies perform in sustainability. We analyse sustainability performance 
in six selected environmental areas. As a benchmark we rely on target values for 2010 set by various European 
institutions. Data for our analysis were retrieved from publicly available resources, e.g. annual, environmental 
and other reports as well as the companies‘ websites.
Scientific aim: Originally, the sustainability concept was initiated in macroeconomics. However, increasing 
number of companies has incorporated it into their strategies. In this paper we aim to determine whether they 
succeeded. We present the contribution to sustainability by top five great players on the field of pharmaceutical 
market in Europe.
Findings This paper found several key issues: there is a little research of environmental impact generated by 
pharmaceutical companies in terms of sustainable value added. Sustainable value added was positive for all 
analysed companies. It means that successful pharmaceutical companies using six analysed environmental 
resources create more value than required by the target set.
Conclusions: Although sustainable value added determines how well (or bad for that matter) a particular 
company uses its resources compared to a benchmark, it does not judge whether using the total capital in 
a company can be considered as sustainable or not. Nevertheless, for comparing environmental results of 
various companies this method is suitable and highly adaptable when using it for analysis of other industries 
or services, as well.
Keywords: benchmarking, environmental performance, green economy, pharmaceutical manufacturers, 
sustainability, sustainable value added
JEL Classification: Q51, Q56
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Introduction
Great societal challenge is built by both the increa-
sing consumption of non-renewable resources and 
continuous growth of anthropogenic emissions. 
Methods valuing these negative externalities are so 
called burden-based methods. They belong to tradi-
tional economical approaches striving effective en-
vironmental protection (Mezřický, 2005). The only 
value-orientated method – sustainable value added 
(SVA) – takes into account the value created by all 
used resources. SVA expresses how much value 
contributed an economic entity to sustainable va-
lue creation. The sustainable value added is created 
when it overcomes the threshold of benchmark (The 
ADVANCE Project, 2006). Thus scarce resources 
used by companies should create at least as much 
value as the benchmark. Otherwise, these resources 
could have been employed where they create more 
value, ceteris paribus (Pearce and Atkinson, 1998).
In this article we aim to assess whether analysed 
companies perform better in environmental areas than 
set benchmark. There are presented the results of an 
analysis of sustainable value added created by top 5 
European companies in the pharmaceutical sector in 
six different environmental resources (CO
2
, NO
x
, SO
2
, 
VOC, waste generated and water used). We compa-
re value created in these respective companies to the 
target EU values. Our results show that companies in 
2010 performed better than the set target and therefore 
all analysed companies can be described as sustainable 
when considering EU targets as benchmark.
Human ingeniousness to use scarce resources by 
various ways enables us to increase requirements for 
comfort in our lives and thus influences or even de-
fines both production and consumption behaviour. 
Such behaviour dictates trends in „modern“ soci-
ety (Pernica and Baštinec, 2012). In holistic point 
of view, this behaviour influences the whole system 
(universe, life, mind, spirit). Both production factors 
and use-and-throw-away life style lead to the incre-
asing resources depletion. It can be easily deduc-
ted that a number of economic collateral damages 
are caused by the environmental problems (Stern, 
2006). Companies have undertaken some measures 
supposed to lead to sustainability even if originating 
in the legislation (Freiberg, 2007).
Providing healthcare is one of society‘s greatest 
concern, it should be scrutinized from environmental 
point of view, as well. Berry and Rondinelli (2000) 
state though the pharmaceutical industry is not brou-
ght into sharper environmental focus, it plays a cer-
tain role in environmental pollution. These authors 
consider impact of pharmaceutical manufacturers 
mostly in areas of carbon dioxide (CO
2
), nitrogen 
oxides (NO
x
), sulphur dioxide (SO
2
) and volatile 
organic compounds (VOC) from systems without 
filters. Besides to these components of pollution, we 
added both waste generated and water used into our 
analysis as other most common sources of environ-
mental impact as it is not possible to produce witho-
ut the by-side effects.
From an economic perspective, we consider a 
pharmaceutical company as defined by Berry and 
Rondinelli (2000), e.g. as an entity of “manufactu-
ring, formulating and processing medicinal chemi-
cals and pharmaceutical products” while finished 
production can be created in many forms, e.g. tablets, 
capsules, suspensions, solutions, etc. The authors 
further explain that factors as aging population, high 
life quality and research progress, respectively, drive 
innovations in pharmaceutical industry. The focus of 
Figure 1  Green economy. Source: European Environment Agency, 2011(retrieved February 2nd 2012).
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pharmaceutical companies will be aimed at diseases 
as hypertension, arthritis, Alzheimer‘s disease and 
other diseases occurring in elder age of live.
Beside medicaments, pharmaceutical companies 
create also negative by-products deteriorating air 
(air emissions, acid gases), water (waste water pol-
lution of rivers, streams and groundwater) and soil 
(residual materials and waste) as solid or volatile 
pollutants (Berry and Rondinelli, 2000). The solu-
tion to these pollution problems can be presented in 
a trend called sustainability. In the last decades, the 
term sustainability has become very popular. Sus-
tainability means behaviour using environmentally-
friendly methods. Sustainability is not the aim; it is 
the way on which humankind is supposed to walk 
if it does not wish to perish by its own doing. The 
sustainability concept on macroeconomic level net 
of its social aspect can be translated into term gre-
en economy (see Figure 1). Green economy intends 
to implement sustainability rules by environmental 
technologies as it links economic success to envi-
ronment issues. It means that finally we are gradu-
ally acknowledging that environment cannot absorb 
all emitted pollutants naturally (European Environ-
ment Agency, 2011).
Green economy applies to pharmaceutical sector 
as green chemistry. It embodies firstly the problem 
of efficient use of raw materials and elimination of 
waste and secondly the problem of health, safety 
and environmental risk exposure related to the che-
micals (Ravichandran, 2011).
Berry (2004) emphasizes the other side of sustai-
nability, especially the need to manage natural resou-
rces more economically. How effective and efficient 
a company is by fulfilling this managerial implicati-
on can be shown via Sustainable Value Added. SVA 
as a whole new method was first introduced in the 
article Sustainable Value Added (Figge and Hahn, 
2004a) though first traces of it are apparent before 
(Figge and Hahn, 2002). These researchers are wor-
king today for both Euromed Management School in 
Marseille and the IZT (Institut für Zukunftsstudien 
und Technologiebewertung, i.e. Institute for Futures 
Studies and Technology Assessment) in Berlin. SVA 
differs from existing approaches because this valu-
e-based method assesses resources by their relative 
contribution to the value added. All other existing 
approaches to sustainability assessment are burden-
based, i.e. resource use is assessed based on the bur-
den that is created. Schaltegger and Figge (2000) 
explain that environmental protection per se does 
not generate any value.
Since introduction of SVA a few studies were ac-
complished mostly by original authors on both the 
macroeconomic and microeconomic level (Figge, 
Hahn, 2004b; Figge, Hahn, 2005; Hahn et al., 2007; 
Van Passel et al., 2009, Rhouma, 2010).
Economic entities are exposed to environmen-
tal issues among others for emissions (to air, water 
and soil), waste and material intensity (Figge et al., 
2002). In this article we answer the question of how 
well do pharmaceutical companies cope with envi-
ronmental issues outlined above by measuring SVA 
in six selected environmental outputs. Data for our 
analysis we gained from annual reports, financial 
statements, environmental reports, other enclosed 
reports and the companies‘ websites.
1.  Weak vs. Strong Sustainability
Various elements of sustainability are usually divided 
into three areas: environmental, economic and social 
area – components of the triple bottom line (Hart and 
Milstein, 2003).The environment is considered to be 
a base for sustainability, economic activity is a tool 
for sustainability and social aspect is an aim of sustai-
nability. Sustainable development occurs when the le-
vel of total capital used (i.e. natural, man-made, social 
and human capital respectively) keeps the same level 
constant over time. This is also known as the constant 
capital rule (Solow, 1986).
If all forms of capital are considered to be per-
fectly substitutable, it can be labelled as weak sus-
tainability. The idea is that the decrease in one form 
of capital is compensated by the increase in other 
(Pearce and Atkinson, 1998).
Some forms of capital do not have substitutes or at 
the very least, a certain minimum level of it should 
be kept to conserve the environment. This approach 
is called strong sustainability. Dietz and Neumayer 
(2007) refer to strong sustainability as a concept fo-
cused more on environmental issue rather than a cost 
driver. However, in sustainability, green economy or 
green chemistry concept environment does not con-
tradict the social and economic benefits, it adds to 
synergy effect, as well. Constanza and Daly (1992) 
support the opinion that strong and weak sustainabi-
lity are not necessarily conflicting. They explain that 
strong sustainability imposes additional conditions 
to the basic constant capital rule.
According to Beckerman (1995), the difference 
between weak and strong sustainability exists (see 
Table 1). Here K stands for capital (all of its forms), 
accordingly K
N
 is natural capital, K
S
 is social capital 
and t is time.
On the other way, Robinson and Boulle (2012) ar-
gue if both natural and social issues are scrutinized 
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by economic principle, economic entity is of weak 
sustainability. Strong sustainability requires putting 
environment as the first priority, then society as the 
second and finally the economic logic. The reason is 
the scarcity of resources where environment is the 
utmost finite followed by social resources while eco-
nomy remains well kept alive.
2.  Methology
SVA gives the answer to the question how much va-
lue a company creates thanks to its environmental 
production factors compared to a benchmark. As the 
benchmark another company, a particular sector, an 
economy or even an internationally set target could 
be used (Figge and Hahn; 2004b).
We build upon the last kind of benchmark (EU 
targets). In this paper we use SVA approach to mea-
sure environmental performance for these respecti-
ve companies: GlaxoSmithKline, Novartis Pharma, 
Fresenius, Sanofi, Vion, Novo Nordisk and Astra-
Zeneca.These top manufacturers of pharmaceutical 
preparations were chosen according to operating 
revenues (category expressing economic value) 
in 2010 as recorded in the Amadeus database.
From seven selected companies, two were excluded. 
Fresenius, though it should be the third in our ranking, 
lacks on environmental data publicly accessible. We 
were not able to gain these data other ways.
The other excluded company Vion, supposed to 
be in the fifth position in ranking, was in our opinion 
mistakenly categorized as pharmaceutical company 
in Amadeus database. Yet Vion‘s business core ac-
tivity is food and ingredients producing, what does 
not fit into our analysed company profile category.
Data for analysed companies were obtained 
through publicly accessible sources, i.e. annual re-
ports, environmental reports, etc. It was essential 
to our analysis to integrate also sources other than 
environmental performance reports as they provided 
us with limited information.
As a benchmark we used target values elaborated 
in the ADVANCE Project (see Table 2) launched in 
Germany (Hahn et al., 2007).
We intentionally have left out value created by 
methane (CH
4
-emissions) because just one company 
has reported data on it. Then the whole sample could 
have not been properly examined.
The SVA of analysed companies was assessed in 
five successive steps (Hahn et al., 2007) ranged al-
phabetically from the first (A) to the last (E).
A. How much of an environmental resource r is 
used by a company? There are considered six en-
vironmental resources.
B. What value of operating revenue (return R) is 
created in a company by these resources?
C. What value of operating revenue (e.g. bench-
mark value, BV) is considered to be a minimum 
to achieve a positive SVA? This is the target T:
 T = r . BV .
D. Which resources contribute to SVA, i.e. positive 
or negative SVA of a resource SVAr
 SVAr = R – T ?
E. How much of total sustainable value added SVAT 
does a company create through all six analysed 
environmental resources? This final result shows 
what economic value was created besides the six 
pollutants, if the EU15 environmental perfor-
mance targets take part in value contribution as a 
benchmark:
 
6
1
r
T
SVA
SVA
r
=
∑
 .
Performance targets considered as the benchmark 
are shown in Table 2. They assess how well resour-
ces had to be used in 2010. When comparing com-
panies with various sizes, large corporations usually 
make greater operating revenues than the small. To 
avoid this size effect, Hahn et al. (2007) propose to 
Table 1  Weak and Strong sustainability rules.
Form of sustainability Requirement
    weak dK / dt ≥ 0
strong
environmental dK / dt ≥ 0 and dK
N 
/ dt ≥ 0
social dK / dt ≥ 0 and dK
s 
/ dt ≥ 0
Source: Beckerman, 19952 Methodology.
Table 2  Target efficiencies of the EU 15 for 2010 in 
selected environmental areas.
Resource r Benchmark value BV
CO2-emissions 3,733 €/t
NOx-emissions 1,933,747 €/t
SOx-emissions 3,151,784 €/t
Waste generated 9,802 €/t
Water used 53 €/m3
VOC-emissions 2,052,245 €/t
Source: The ADVANCE Project (2006).
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use Return to Cost Ratio (RCR). It is constructed as 
ratio between return and average benchmark value 
of resources used (in the case where return is greater 
than average BV. In other case, these variables are 
compared in reverse order.):
 RCR = R:BV
average 
.
If the ratio is e.g. 3.78:1 (the case of GSK) the 
company created € 3.78 whereas benchmark would 
have created € 1 by the same resources.
3.  Results
The analysed companies were chosen as top compa-
nies with the highest operating revenues in 2010 ac-
cording to Amadeus database. The pharmaceutical 
companies selected can be seen in Table 3.
The figures in all calculations are rounded accor-
ding to the custom, auxiliary data are presented in € 
mil, the final data (SVAT) in € bn.
Data were collected either from 2010 reports or 
where more accurate, from 2011 reports. The ab-
sent data were experienced just by NovoNordisk in 
their VOC-emissions. We contacted the corporation 
via e-mail but to this date no answer was obtained. 
The other data inconsistency is apparent in SO
x
-e-
missions as some corporations do enclose this in-
formation; others enclose information just for SO
2
-
emissions. We decided to consider SO
2
-emissions as 
SO
x
-emissions because the major part of SO
x
-emis-
sions consists primarily of SO
2
-emissions. For three 
corporations (GSK, Novartis Pharma and AstraZe-
neca) no explicit information about CO
2
-emissions 
was present. We took into account just their green-
house gas emissions (GHG). Generally, they com-
prise of about 99 per cent of CO
2
-emissions. This 
equal consideration is clearly marked in the analyses 
of the respective companies by marking estimated in 
brackets. NO
x
 and SO
2
-emissions for GSK were not 
enclosed in any of its reports.
The final ranking of analysed companies accor-
ding to sustainable value added will be presented in 
the Final results section.
The next sub-chapters are draft in the fashion: 
firstly we present concise information about each 
respective company, then we calculate the actual 
SVA (assessment of the SVA is easy to follow in 
the respective tables according to steps described in 
the Methodology part) followed by the explanation 
of the results. Finally, for each company we sketch 
possible areas of improvements and current activi-
ties undertaken in a company in environmental is-
sues.
3.1  GlaxoSmithKline
GlaxoSmithKline Plc (henceforth GSK) is one of 
the biggest pharmaceutical companies in the world 
based in London. In 2000, GSK was formed throu-
gh the merger of Glaxo Wellcome and SmithKline 
Beecham. Its main business is research and develo-
pment, manufacturing and merchandising of various 
types of medicals. The corporation claims to deve-
lop effective and safe drugs of the highest quality 
(GlaxoSmithKline, 2011).
In the environmental area, the corporation would 
like to benefit both the environment and itself by 
reducing its annual costs through reduced energy, 
materials and distribution costs (GlaxoSmithKline, 
2011). The greatest weakness for the corporation 
is its pollution of carbon dioxide emissions (see 
Table 4) because in this area it creates the lowest 
sustainable value added.
In its Corporate Responsibility Report, GSK 
(2011) publicly worries about exactly these emis-
sions seeing that carbon dioxide and other emissions 
contribute to climate change.
The corporation has implemented life cycle as-
sessment (LCA) of its key products. This behaviour 
is motivated by GSK’s business strategy, its risk 
management, stakeholder interests (including inves-
Table 3  Pharmaceutical Company Characteristics.
Rank Company Headquarter Operating Revenues in 2010 Employees Major Product Groups
1 GlaxoSmithKline London € 33,841 mil 99,913
Pharmaceuticals, drugs, 
dermatological products
2 Novartis Pharma Basel € 26,663 mil 99,834
Pharmaceuticals, generics 
products, health product
3 Sanofi Paris € 11,105 mil 101,575
Pharmaceuticals, human 
vaccines, animal care
4 Novo Nordisk Bagsværd € 8,154 mil 32,500
Pharmaceuticals, diabetes 
care, hormone therapy
5 AstraZeneca Södertälje € 7,074 mil 62,700
Pharmaceuticals, inhibitors, 
anaesthesia drugs
Source: Own elaboration.
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tor feedback), changes in operations (for products 
and markets, see also Ansoff matrix), existing and 
proposed legislation and public opinion supported 
by media communication (GlaxoSmithKline, 2011). 
We recommend providing stakeholders with LCA 
outcome. We express our support to apply this as-
sessment further on to whole product lines.
The corporation also tries to reduce the full en-
vironmental footprint of the products. According 
to the environmental sustainability goals the value 
chain should be carbon neutral by 2050. This has to 
be achieved through disaggregated goals presented 
as reduced both carbon footprint (by 25 %) and wa-
ter usage (by 20%) by 2020 in comparison to 2006 
(GlaxoSmithKline, 2011).
Other environmental practice in the corporation is 
its requirement on potential new critical suppliers to 
fulfil standards on environment, health and safety is-
sues (GlaxoSmithKline, 2011). LCA confirmed the 
necessity to recognize the responsibility of suppli-
ers through grants into green chemistry as 40% of 
GSK’s carbon footprint results from its supply chain 
(GlaxoSmithKline, 2011). GSK (2011) plans to re-
duce overall carbon footprint across the value chain 
by 10% by 2015 compared to data from 2010 report. 
We wish GSK to meet this number.
3.2  Novartis Pharma
Novartis Pharma (henceforth Novartis) was esta-
blished in 1996 through the merger of Ciba-Geigy 
and Sandos. It operates globally with its headquarter 
in Basel. Novartis is active in research and deve-
lopment of medicaments and is a part of 2010 UN 
Global Compact Communication on Progress prin-
ciples on environment. From all analysed inputs, 
Novartis is the worst off in water used (Table 5).
Furthermore, of our entire sample it uses the gre-
atest amount of water as a resource, mostly for coo-
ling purposes (Novartis, 2012). Cooling is required 
for the control of fermentation processes and for air 
conditioning mechanisms in offices.
In the corporation, water is acquired twofold. 
Around 28 per cent of water is purchased and other 
72 per cent is abstracted from groundwater wells 
(Novartis, 2012).
Self-induced target for water efficiency for 2011 
(4% improvement of 2010 figures) was not met, mo-
reover, the efficiency even declined. For 2012, the 
target remains unchanged as water efficiency should 
increase by mentioned 4% in comparison to 2010 
(Novartis, 2012).
From actual emissions, carbon dioxide shows the 
worst results. The corporation committed itself to re-
Table 4  The SVA of GlaxoSmithKline in 2010.
Resource r (t) Return R (€) Target T (€) SVAr (€)
CO2-emissions 6,900,000 (estimated) 33,841 mil 25,758 mil 8,083 mil
NOx-emissions n.a. n.a. n.a. n.a. mil
SOx-emissions n.a. n.a. n.a. n.a. mil
Waste generated 361,000 33,841 mil 3,539 mil 30,302 mil
Water used (m3) 18,700,000 33,841 mil 991 mil 32,850 mil
VOC-emissions 2,700 33,841 mil 5,541 mil 28,300 mil
SVAT 24.9 bn
Return to Cost Ratio 3.78 : 1
Source: own analysis based on GSK (2011) and publicly enclosed data.
Table 5  The SVA of Novartis in 2010.
Resource r (t) Return R (€) Target T (€) SVA
r
 (€)
CO
2
-emissions 1,509,910 (estimated) 26,663 mil 5,636 mil 21,027 mil
NO
x
-emissions 313 26,663 mil 605 mil 26,058 mil
SO
2
-emissions 82 26,663 mil 258 mil 26,405 mil
Waste generated 279,830 26,663 mil 2,743 mil 23,920 mil
Water used (m3) 90,900,000 26,663 mil 4,817 mil 21,846 mil
VOC-emissions 1,521 26,663 mil 3,121 mil 23,542 mil
SVAT 23.8 bn
Return to Cost Ratio 9.31 : 1
Source: own analysis based on Novartis (2012) and publicly enclosed data.
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duction of CO
2
 emissions from vehicle by using 1,315 
hybrid gasoline-electric cars and 99 fuel efficient cars 
(thanks to filtered diesel engines) and switching to li-
quid natural gas or bio-fuels as propellants (Novartis, 
2012). Yet, we do not agree with incorporation of bio-
fuels since it does not bode well with green economy 
principles. Firstly, they need huge amount of water for 
their growth and secondly, instead of their outplanting 
other crops supposed for eating (such as wheat) could 
have been sowed. Thirdly, biomass results in SO
x
 and 
NO
x
 air pollution.
3.3  Sanofi
In August 2004, Sanofi-Synthelabo acquired Aven-
tis, while the takeover was accomplished in Decem-
ber 31st of that year, giving birth to sanofi-aventis. 
On May 6th 2011, sanofi-aventis simplified its name 
to Sanofi.
As can be seen in Table 6, Sanofi‘s most proble-
matic emission is carbon dioxide. These emissions 
are generated during manufacturing of medicines. 
Other factors causing this status quo are steam and 
hot water as auxiliary production factors, as well as 
business related tasks, e.g. transport of goods, bu-
siness travel, employee commuting, organization of 
seminars, etc. The corporation set the goal of car-
bon dioxide decrease as 15% reduction by the end 
of 2013.
In VOC area, other sore subject of Sanofi‘s sustai-
nable value added, in 2010, Sanofi placed bio filter 
into production instead of thermal oxidation proces-
ses. For several years, the corporation has developed 
new formulas for aqueous solution replacing those 
creating VOC. Therefore, it was possible to decrease 
annual VOC-emissions (Sanofi, 2011).
Water use accounts for average results in SVA 
generation. Sanofi (2011) states it consumes water 
during various stages of industrial processes (fer-
mentation, vaccine manufacturing), for cleaning and 
cooling. The measurements for water decrease are in 
the corporation seen in closed-loop cooling facilities 
and recycling technology (especially in plants with 
high risk of water scarcity such as in Turkey or in 
Africa).
3.4  Novo Nordisk
Novo Nordisk manufactures pharmaceutical produ-
cts and services. Since 1989, when it was established 
by a merger of two Danish companies, it has beco-
me one of the world‘s leading companies in diabe-
tes care pursuing research into pulmonary delivery 
systems and insulin pump systems, hormone repla-
cement therapy, autoimmune and chronic inflam-
matory diseases using state-of-the-art technologies 
such as translational immunology and monoclonal 
antibodies.
Table 6  The SVA of Sanofi in 2010.
Resource r (t) Return R (€) Target T (€) SVAr (€)
CO2-emissions 1,211,411 11,105 mil 4,522 mil 6,583 mil
NOx-emissions 370 11,105 mil 715 mil 10,390 mil
SOx-emissions 39 11,105 mil 123 mil 10,982 mil
Waste generated 230,843 11,105 mil 2,263 mil 8,842 mil
Water used (m3) 55,818,172 11,105 mil 2,958 mil 8,147 mil
VOC-emissions 2,058 11,105 mil 4,224 mil 6,881 mil
SVAT 8.6 bn
Return to Cost Ratio 4.44 : 1
Source: own analysis based on Sanofi (2011) and publicly enclosed data.
Table 7  The SVA of Novo Nordisk in 2010.
Resource r (t) Return R (€) Target T (€) SVAr (€)
CO2-emissions 158,000 8,154 mil 590 mil 7,564 mil
NOx-emissions 121 8,154 mil 234 mil 7,920 mil
SO2-emissions 119 8,154 mil 375 mil 7,779 mil
Waste generated 20,565 8,154 mil 202 mil 7,952 mil
Water used (m3) 2,047,000 8,154 mil 108 mil 8,046 mil
VOC-emissions n.a. 8,154 mil n.a. n.a.
SVAT 7.8 bn
Return to Cost Ratio 27.00 : 1
Source: own analysis based on Novo Nordisk(2011) and publicly enclosed data.
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The calculation of both the SVA and Return to 
Cost Ratio for 2010 can be seen in Table 7.
Novo Nordisk has been focusing on its use of 
resources, emissions and waste since 1975. Since 
2002, the corporation has been reporting its envi-
ronmental performance in accordance with the GRI 
Sustainability Reporting Guidelines.
The corporation states (Novo Nordisk, 2011) that 
more emphasis will be placed on pollution preven-
tion through sustainable design of processes and 
products. The principles of sustainable development 
resonate well with the philosophy upon which Novo 
Nordisk was founded – and it showed in our results, 
too.
The Return to Cost Ratio can be interpreted along 
these lines (Figge and Hahn, 2004a): In 2010, Novo 
Nordisk should create € 1 of value added from ana-
lysed environmental components. Instead, it crea-
ted € 27 and therefore generated positive SVA. In 
comparison to other analysed corporations, Novo 
Nordisk generated low operational revenues. On the 
other hand, its use of environmental resources has 
shown low figures, too. Therefore, Novo Nordisk 
is shining example for other corporations as how to 
use resources effectively and efficiently.
3.5  AstraZeneca
AstraZeneca was formed in April 6th1999 throu-
gh the merger of Astra AB (Sweden) and Zeneca 
Group PLC (United Kingdom). Key products focus 
on pharmaceuticals, agrochemicals and treatment 
of oncology, cardiovascular and respiratory disea-
ses, central nervous system disorders, anaesthesia 
and other diseases. The products are manufactured 
in 19 facilities located in 15 countries all over the 
world.
From all analysed companies, AstraZeneca shows 
the least value created by VOC. They are important 
because they create photochemical ozone in tropo-
sphere but VOC-emissions lead to smog and other 
negative effects on both human health and environ-
ment, as well. The corporation has set no particu-
lar target in this area. We recommend to look after 
VOC-emissions and maybe to categorise them to 
halogenated and non-halogenated to manage them 
appropriately.
However, AstraZeneca aims to reduce its footprint 
by 20% till 2015 when compared to 2010 baseline 
(AstraZeneca, 2011).
AstraZeneca is successful in water management, 
evident also in sustainable value created. Its actual 
target is to reduce absolute water use by 25% by the 
end of 2015 compared to 2010 (AstraZeneca, 2011). 
This objective is very ambitious in contrast with 
competitive corporations of our analysis who seems 
to have problems with or at least show mediocre re-
sults in water use.
AstraZeneca manages waste very well, too. Tar-
gets to meet till 2015 are set like this: the half of 
waste generated should be recycled, recovered and 
reused and non-hazardous waste landfilled should 
decrease from current 23 per cent to 10 per cent. 
Both target values refer to 2010 data (AstraZeneca, 
2011).
Its green chemistry initiatives include training of 
the staff in environmental issues.
3.6  Final results
The best corporation in creating positive SVA from 
the analysed companies turns out to be Novo Nor-
disk. With its return to cost ratio (result 27:1 explai-
ned in the section 3.4) the corporation far exceeds 
the competitors though the actual absolute amount 
of sustainable value created is the second lowest 
(€ 7.8 bn). In the second place is Novartis with RCR 
9.31:1 and absolute amount of SVA € 23.8 bn. The 
third place is held by AstraZeneca (7.11:1) with 
the lowest absolute amount of SVA (€ 6.1 bn). In 
the fourth place of our ranking is Sanofi with RCR 
4.4:1 and absolute level of SVA € 8.6 bn. The least 
successful corporation was GlaxoSmithKline, the 
corporation with the highest absolute level of SVA 
Table 8  The SVA of AstraZeneca in 2010.
Resource r (t) Return R (€) Target T (€) SVA
r
 (€)
CO
2
-emissions 1,080,000 (estimated) 7,074 mil 4,032 mil 3,042 mil
NO
x
-emissions 266 7,074 mil 514 mil 6,560 mil
SO
x
-emissions 24 7,074 mil 76 mil 6,998 mil
Waste generated 44,000 7,074 mil 431 mil 6,643 mil
Water used (m3) 4,000,000 7,074 mil 212 mil 6,862 mil
VOC-emissions 343 7,074 mil 704 mil 6,370 mil
SVAT 6.1 bn
Return to Cost Ratio 7.11 : 1
Source: own analysis based on AstraZeneca (2011) and publicly enclosed data.
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(€  4.9 bn) but not so good in RCR (3.78 to one). We 
would like to emphasize the fact that all analysed 
companies generated positive SVA.
Nonetheless, we conclude that exceptionally good 
results in SVA achieved are from a greater part in-
fluenced not by effective and efficient use of resour-
ces but rather by good economic results. It is widely 
known that pharmaceuticals are neutral goods and 
the demand on them would be present regardless of 
economic situation of population. This fact alone 
causes that pharmaceuticals are sold with extremely 
high margin.
4.  Discussion
As can be seen from brief description of each and 
every analysed company, the pharmaceutical indu-
stry (like any industry) is in Europe led by immense 
mergers and acquisitions. Besides ethical concerns 
resulting from pharmaceutical research practices, 
environmental concern should not be neglected. 
Moreover, environmental reports should be the DNA 
of pharmaceutical corporations. The environmental 
performance reports of leading European pharma-
ceutical corporations recognize their environmental 
duties in data enclosing on pollution prevention. 
Emissions and environmental impact of pharmaceu-
tical corporations are influenced by solvent-based 
production. Pharmaceutical corporations affect en-
vironment in many ways, especially in water usage, 
waste and emissions resulting from production of 
active ingredients and the formulation of medicines, 
drugs or vaccines.
Corporations are aware of demands arisen from 
stakeholders‘ groups to implement technologies 
reducing waste, water and pollutants and therefore 
minimize negative environmental impacts. In return, 
corporations expect to gain competitive advantage 
in cost savings, increased efficiency and lesser en-
vironmental risks.
Beyond that, some issues are related to enclosing 
environmental data in not very great detail. Firstly, 
the non-transparency does not bode well with com-
pany‘s image built by eco-marketing strategies and 
secondly, undertaken actions declared by companies 
cannot be taken seriously while not backed up with 
hard data.
Conclusion
In the context of sustainable development it is impe-
rative to widen financial perspective of business by 
other forms of capital, i.e. natural, man-made, social 
and human. Sustainable value added includes these 
various forms of capital. The analysis of corporate 
environmental performance with this approach pro-
vides soft factors expressed in hard numbers well 
understandable for managerial way of decision ma-
king.
The Achilles heel of this method is its disability to 
clearly define whether a company uses all forms of 
its capital in a sustainable way or not. This method 
just shows how much a particular company con-
tributed to sustainability in comparison to a chosen 
benchmark.
Despite its obvious weakness, this method is ap-
plicable and has a great potential to be implemented 
in the real business world because it is novel from 
the way it is calculated. The novelty lays in value-
based assessment of environmental impact. SVA is 
based on the rationale that emissions would be pol-
luted in any case, the question is how much econom-
ic value (expressed by various economic categories) 
a producer delivers.
Further implementation of this method is needed 
both in macroeconomic and microeconomic analy-
sis. The research has not been conducted in many 
companies, sectors or economies yet. This provides 
us with great opportunity to compare various eco-
nomic entities from sector perspective, geographi-
cally and in a time span.
Green economy and sustainability principles 
could lead our world out of current economic and 
also ethical crisis to the brighter future. Tools for 
implementing these ideas are here, what we need is 
just heading the sea.
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